

SB 2659

SD1 HD1

A BILL FOR AN ACT

RELATING TO MEDICAL CANNABIS PRODUCTS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. The legislature finds that the list of medical
2 cannabis products that may be manufactured and distributed
3 pursuant to section 329D-10, Hawaii Revised Statutes, omits
4 viable products. The legislature notes that the Act 230,
5 Session Laws of Hawaii 2016, medical cannabis legislative
6 oversight working group recommended updating transdermal patches
7 to transdermal devices, as excluding non-patch devices that
8 deliver through the dermis was unintentional. The working group
9 also recommended adding suppositories to the list, due to the
10 advantages suppository delivery provides as a form of drug
11 administration: it avoids the first-pass metabolic effects of
12 oral ingestion, leading to sustained elevation of drug plasma
13 levels, and it is a favorable option for patients who have
14 difficulty with oral administration.

15 The purpose of this Act is to further ensure access to
16 medical cannabis for qualifying patients, by updating references
17 in the medical cannabis dispensary laws from transdermal patches



1 to transdermal devices and by adding cannabinoid suppositories
2 to the list of manufactured cannabis products that may be
3 manufactured and distributed by dispensaries.

4 SECTION 2. Section 329D-1, Hawaii Revised Statutes, is
5 amended as follows:

6 1. By adding a new definition to be appropriately inserted
7 and to read:

8 "Cannabinoid suppository" means a small, soluble container
9 designed to melt at body temperature within a body cavity other
10 than the mouth, especially the rectum or vagina, containing a
11 cannabinoid product, concentrate, or extract."

12 2. By amending the definition of "manufactured cannabis
13 product" to read:

14 "Manufactured cannabis product" means any [capsule,
15 lozenge, oil or oil extract, tincture, ointment or skin lotion,
16 pill, transdermal patch, or pre-filled and sealed container used
17 to aerosolize and deliver cannabis orally, such as an inhaler or
18 nebulizer,] product that has been manufactured using cannabis [,
19 or any other products as specified by the department] pursuant
20 to section [~~329D-10(a)(9).~~] 329D-10."



1 SECTION 3. Section 329D-10, Hawaii Revised Statutes, is
2 amended by amending subsection (a) to read as follows:

3 "(a) The types of medical cannabis products that may be
4 manufactured and distributed pursuant to this chapter shall be
5 limited to:

- 6 (1) Capsules;
- 7 (2) Lozenges;
- 8 (3) Pills;
- 9 (4) Oils and oil extracts;
- 10 (5) Tinctures;
- 11 (6) Ointments and skin lotions;
- 12 (7) Transdermal [~~patches,~~] devices;
- 13 (8) Pre-filled and sealed containers used to aerosolize
14 and deliver cannabis orally, such as with an inhaler
15 or nebulizer; [~~and~~]
- 16 (9) Cannabinoid suppositories; and
- 17 [~~(9)~~] (10) Other products as specified by the department."

18 SECTION 4. Statutory material to be repealed is bracketed
19 and stricken. New statutory material is underscored.

20



1 SECTION 5. This Act shall take effect on July 1, 3000.



Report Title:

Medical Cannabis; Manufactured Cannabis Products; Transdermal Devices; Suppositories

Description:

Updates transdermal patches to transdermal devices in section 329D-10, Hawaii Revised Statutes, thereby including non-patch devices that deliver through the dermis. Adds cannabinoid suppositories to the list of cannabis products that may be manufactured and distributed by dispensaries. (SB2659 HD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.



SB-2659-HD-1

Submitted on: 3/20/2018 1:13:27 PM

Testimony for CPC on 3/21/2018 2:15:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Carl Bergquist	Drug Policy Forum of Hawaii	Support	No

Comments:

Both transdermal devices and suppositories are cutting edge modes capable of delivering medical cannabis to registered patients. Allowing dispensaries to sell and/or produce these increases options for patients who may have few others.

Mahalo for the opportunity to testify.